Retour à l'index des publications
Export 24 results:
Warning on RTF export
×
If you export in RTF and open your file with microsoft Word, you need to choose "Occidental (Windows Latin 1)" encoding.

Journal Article

  1. [BOSC-15b]G. Boschetti, Laidet, M., Moussata, D., Stefanescu, C., Roblin, X., Cotte, E., Passot, G., François, Y., Drai, J., Del Tedesco, E., Bouhnik, Y., Flourié, B., and Nancey, S., “Levels of Fecal Calprotectin Are Associated With the Severity of Postoperative Endoscopic Recurrence in Asymptomatic Patients With Crohn's Disease”, Am J Gastroenterol, 2015.
  2. [MOUS-15a]D. Moussata, Stroeymeyt, K., Boschetti, G., Chauvenet, M., Nancey, S., Berger, F., Lecomte, T., and Flourié, B., “Endoscopic and histologic characteristics of serrated lesions.”, World J Gastroenterol., vol. 21, 2015.
  3. [PETI-15]B. Petit, Boschetti, G., Passot, G., Chauvenet, M., Cotte, E., Stroeymeyt, K., Nancey, S., Vaudoyer, D., François, Y., Cabelguenne, D., Glehen, O., Flourié, B., and Moussata, D., “Abdominal necrotic abscess from colonic fistula treated endoscopically”, Gastrointest Endosc, vol. 81, 2015.
  4. [BOSC-15a]G. Boschetti, Garnero, P., Moussata, D., Cuerq, C., Préaudat, C., Duclaux-Loras, R., Mialon, A., Drai, J., Flourié, B., and Nancey, S., “Accuracies of serum and fecal S100 proteins (calprotectin and calgranulin C) to predict the response to TNF antagonists in patients with Crohn's disease”, Inflamm Bowel Dis., vol. 21, 2015.
  5. [BOSC-14]G. Boschetti, Nancey, S., Moussata, D., Stefanescu, C., Roblin, X., Chauvenet, M., Stroeymeyt, K., Bouhnik, Y., and Flourié, B., “Tacrolimus induction followed by maintenance monotherapy is useful in selected patients with moderate-to-severe ulcerative colitis refractory to prior treatment.”, Dig Liver Dis, vol. 46, 2014.
  6. [NANC-13]S. Nancey, Boschetti, G., Moussata, D., Cotte, E., Peyras, J., Cuerq, C., Haybrard, J., Charlois, A. L., Mialon, A., Chauvenet, M., Stroeymeyt, K., Kaiserlian, D., Drai, J., and Flourié, B., “Neopterine is a novel reliable fécal marker as accurate as calprotectine for predicting endoscopic disease activity in patients with inflammatory bowel diseases.”, Inflamm Bowel Dis, 2013.
  7. [PIOC-13]M. Pioche, Boschetti, G., Cotte, E., Graber, I., Moussata, D., François, Y., Berger, F., Nancey, S., and Flourié, B., “Human herpesvirus 8-associated colorectal Kaposi's sarcoma occurring in a drug-induced immunocompromised patient with refractory ulcerative colitis: Report of a new case and review of the literature.”, Inflamm Bowel Dis, 2013.
  8. [NANC-13c]S. Nancey, Boschetti, G., Moussata, D., Cotte, E., Peyras, J., Cuerq, C., Haybrard, J., Charlois, A. - L., Mialon, A., Chauvenet, M., Stroeymeyt, K., Kaiserlin, D., Drai, J., and Flourié, B., “Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases”, Inflamm Bowel Dis., vol. 19, p. 10, 2013.
  9. [JOUE-13]P. Jouët, Moussata, D., Duboc, H., Boschetti, G., Attar, A., Gorbatchef, C., Sabaté, J. - M., Coffin, B., and Flourié, B., “Effect of short-chain fatty acids and acidification on the phasic and tonic motor activity of the human colon.”, Neurogastroenterol Motil., vol. 25, p. 7, 2013.
  10. [NANC-13b]S. Nancey, Boschetti, G., Moussata, D., Hequet, O., Roblin, X., and Flourié, B., “Letter: extracorporeal photopheresis in refractory chronic active ulcerative colitis”, Aliment Pharmacol Ther., vol. 38, 2013.
  11. [MOUS-12b]D. Moussata, Bessayah, A., Chauvenet, M., Stroeymeyt, K., Boschetti, G., Nancey, S., Cotte, E., Glehen, O., Issac, S., Mornex, F., Freyer, G. Lombard-Bohas C, F., Lombard-Bohas, C., and Flourié, B., “A pathologic complete response in the surgical specimen after systemic chemotherapy for a gallbladder carcinoma”, Gastrointest Cancer Res, vol. 5, 2012.
  12. [NANC-12]S. Nancey, Boschetti, G., Cotte, E., Ruel, K., Almeras, T., Chauvenet, M., Stroeymeyt, K., Moussata, D., Kaiserlian, D., and Flourié, B., “Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab is associated with a profound long-lasting depletion of Foxp3 (+) regulatory T cells: A mechanistic explanation for ipilimumab-induced severe enterocolitis?”, Inflamm Bowel Dis, vol. 18, 2012.
  13. [MOUS-12a]D. Moussata, Amara, S., Decaussin, M., Mornex, F., Gerard, J. P., Romestaing, P., Berger, F., Rödel, F., Flourié, B., Benahmed, M., and Mauduit, C., “XIAP as a radioresistance factor and prognostic marker for radiotherapy in rectal adenocarcinoma. ”, Am J Pathol. , vol. 181, 2012.
  14. [BOSC-11]G. Boschetti, Cotte, E., Moussata, D., Chauvenet, M., Breysse, F., Chomarat, M., Isaac, S., Berger, F., Kaiserlian, D., Nancey, S., and Flourié, B., “Identification of Mycobacterium cosmeticum sp. as a novel colitogenic infectious agent in a nonimmunocompromised patient.”, Inflamm Bowel Dis, vol. 17, 2011.
  15. [MOUS-11]D. Moussata, Goetz, M., Gloeckner, A., Kerner, M., Campbell, B., Hoffman, A., Biesterfeld, S., Flourié, B., Saurin, J. C., Galle, P. R., Neurath, M. F., Watson, A. J., and Kiesslich, R., “Confocal laser endomicroscopy is a new imaging modality for recognition of intramucosal bacteria in inflammatory bowel disease in vivo.”, Gut, vol. 60, 2011.
  16. [NANC-09]S. Nancey, Moussata, D., Roman, S., Benmansour, H., Claudel, S., and Flourié, B., “A positive breath hydrogen test does not predict the occurrence of a spontaneous bacterial peritonitis in cirrhotic patients with ascites.”, Digestion, vol. 79, p. 8, 2009.
  17. [VIEN-09]S. Viennot, Deleporte, A., Moussata, D., Nancey, S., Flourié, B., and Reimund, J. - M., “Colon cancer in inflammatory bowel disease: recent trends, questions and answers.”, Gastroenterol Clin Biol, vol. 33, 2009.
  18. [NANC-08a]S. Nancey, Perret-Liaudet, A., Moussata, D., Graber, I., Boschetti, G., Renaud, B., Kaiserlian, D., Reimund, J. M., and Flourié, B., “Urinary neopterin is a valuable tool in monitoring Crohn's disease activity.”, Inflamm Bowel Dis, vol. 14, 2008.
  19. [NANC-08b]S. Nancey, Hamzaoui, N., Moussata, D., Graber, I., Bienvenu, J., and Flourié, B., “Serum interleukin-6, soluble interleukin-6 receptor and Crohn's disease activity. ”, Dig Dis Sci, vol. 53, 2008.
  20. [ACHO-07]L. Achour, Nancey, S., Moussata, D., Graber, I., Messing, B., and Flourié, B., “Faecal bacterial mass and energetic losses in healthy humans and patients with a short bowel syndrome.”, Eur J clin Nutr, vol. 61, 2007.
  21. [NANC-07]S. Nancey, Moussata, D., and Flourié, B., “Ulcerative colitis and anti-TNFalpha”, Gastroenterol Clin Biol, vol. 31, p. 7, 2007.
  22. [NANC-05]S. Nancey, Moussata, D., Roman, S., Andre, F., Bouvier, M., Claudel, S., Descos, L., Andre, C., and Flourié, B., “Food and digestive allergies in adults”, Gastroenterol Clin Biol, vol. 29, p. 11, 2005.
  23. [NANC-05]S. Nancey, Moussata, D., Graber, I., Claudel, S., Saurin, J. C., and Flourié, B., “Tumor necrosis factor alpha reduces butyrate oxidation in vitro in human colonic mucosa: a link from inflammatory process to mucosal damage?”, Inflamm Bowel Dis, vol. 11, 2005.
  24. [FLOU-03]B. Flourié, Moussata, D., Nancey, S., Bonvoisin, S., Benhamed, M., and Descos, L., “Cancer and inflammatory bowel diseases”, Gastroenterol Clin Biol, vol. 27, p. 7, 2003.